SOPHiA GENETICS (NASDAQ:SOPH) CTO Sells $42,906.08 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CTO Abhimanyu Verma sold 5,284 shares of the firm’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $8.12, for a total transaction of $42,906.08. Following the transaction, the chief technology officer directly owned 166,887 shares of the company’s stock, valued at approximately $1,355,122.44. This represents a 3.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Abhimanyu Verma also recently made the following trade(s):

• On Monday, August 24th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.80, for a total transaction of $44,000.00.
• On Wednesday, August 19th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $8.20, for a total transaction of $41,000.00.
• On Friday, August 7th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.60, for a total value of $38,000.00.
• On Tuesday, August 4th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.95, for a total value of $34,750.00.

SOPHiA GENETICS Stock Down 3.1%

NASDAQ SOPH traded down $0.23 on Wednesday, hitting $7.15. 432,750 shares of the stock traded hands, compared to its average volume of 308,157. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58. The stock has a 50-day moving average of $7.82 and a 200 day moving average of $6.12. SOPHiA GENETICS SA has a twelve month low of $3.75 and a twelve month high of $8.98. The company has a market capitalization of $599.81 million, a P/E ratio of -6.22 and a beta of 0.95.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.The firm had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. As a group, analysts expect that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Trending Headlines about SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Brokerages reportedly have a consensus price target of $10.00 for SOPHiA GENETICS, suggesting potential upside from recent trading levels if the company meets analyst expectations. SOPHiA GENETICS SA Stock Has Consensus Target Price of $10.00 According to Brokerages
• Neutral Sentiment: A comparison article examined SOPHiA GENETICS against Weave Communications, but the item did not identify a specific new company development or change to SOPH’s outlook. Critical Comparison: Weave Communications vs. SOPHiA GENETICS
• Negative Sentiment: Company insiders collectively sold approximately 82,298 shares worth $668,827, including sales by Chairman Jurgi Camblong, CEO Ross Muken, CFO George Cardoza, CTO Abhimanyu Verma and other executives. The transactions reduced their individual holdings by roughly 0.15% to 3.55%, creating near-term selling pressure and potentially weighing on investor sentiment. However, all reported sales were pre-arranged and explicitly made to satisfy tax obligations rather than indicating discretionary selling. SEC insider transaction filing

Analyst Ratings Changes

A number of analysts have weighed in on the stock. BTIG Research increased their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. HC Wainwright increased their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Finally, Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, SOPHiA GENETICS currently has a consensus rating of “Hold” and a consensus price target of $10.00.

Institutional Investors Weigh In On SOPHiA GENETICS

Several large investors have recently added to or reduced their stakes in SOPH. AWM Investment Company Inc. bought a new stake in SOPHiA GENETICS in the second quarter valued at $9,809,000. Principal Financial Group Inc. grew its position in shares of SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after acquiring an additional 9,800 shares during the last quarter. Hodges Capital Management Inc. acquired a new stake in shares of SOPHiA GENETICS in the 1st quarter worth about $2,157,000. Sei Investments Co. bought a new stake in SOPHiA GENETICS in the 1st quarter valued at about $1,772,000. Finally, 1492 Capital Management LLC lifted its position in SOPHiA GENETICS by 8.4% in the 1st quarter. 1492 Capital Management LLC now owns 225,751 shares of the company’s stock valued at $1,117,000 after purchasing an additional 17,406 shares during the last quarter. 31.59% of the stock is owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.